Literature DB >> 7475418

Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease.

M M Schapira1, T L McAuliffe, A B Nattinger.   

Abstract

The objective of this study is to evaluate differences in treatment for localized prostate cancer in African-American compared with Caucasian men. A cohort of patients was identified from the 1988-1989 Surveillance, Epidemiology, and End Results data base. Data were linked by county of residence to the Area Resource File. The main outcome measures were (1) the receipt of aggressive therapy (radical prostatectomy or external beam radiation) and (2) the treatment modality (radical prostatectomy or external beam radiation). Of 5,786 subjects, 15% were treated with a radical prostatectomy, 29% received external beam radiation, and 56% did not receive aggressive therapy. African Americans were less likely (relative risk 0.46; 95% confidence interval 0.39, 0.54) than Caucasians to receive aggressive therapy. Among those receiving aggressive therapy, African Americans were less likely (relative risk 0.64; 95% confidence interval 0.48, 0.86) than Caucasians to have a radical prostatectomy. Adjustment for patient, disease, and community health care availability characteristics did not change these results. We conclude that African-American and Caucasian men receive different treatments for localized prostate cancer. The reasons for the differences, and their ultimate effect on mortality and quality of life require further study.

Entities:  

Mesh:

Year:  1995        PMID: 7475418     DOI: 10.1097/00005650-199511000-00002

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  24 in total

1.  African-American Men with Low-Risk Prostate Cancer: Modern Treatment and Outcome Trends.

Authors:  Augustine C Obirieze; Ambria Moten; Delenya Allen; Chiledum A Ahaghotu
Journal:  J Racial Ethn Health Disparities       Date:  2014-12-16

2.  Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Authors:  Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-25       Impact factor: 4.254

3.  Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urol Oncol       Date:  2016-05-06       Impact factor: 3.498

4.  Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.

Authors:  R C Bergan; R G Walls; W D Figg; N A Dawson; D Headlee; A Tompkins; S M Steinberg; E Reed
Journal:  J Natl Med Assoc       Date:  1997-09       Impact factor: 1.798

5.  Life-Threatening Disparities: The Treatment of Black and White Cancer Patients.

Authors:  Louis A Penner; Susan Eggly; Jennifer J Griggs; Willie Underwood; Heather Orom; Terrance L Albrecht
Journal:  J Soc Issues       Date:  2012-06-25

6.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

7.  Race, healthcare access and physician trust among prostate cancer patients.

Authors:  Young Kyung Do; William R Carpenter; Pamela Spain; Jack A Clark; Robert J Hamilton; Joseph A Galanko; Anne Jackman; James A Talcott; Paul A Godley
Journal:  Cancer Causes Control       Date:  2009-09-24       Impact factor: 2.506

8.  The contribution of cancer incidence, stage at diagnosis and survival to racial differences in years of life expectancy.

Authors:  Mitchell D Wong; Susan L Ettner; W John Boscardin; Martin F Shapiro
Journal:  J Gen Intern Med       Date:  2009-02-03       Impact factor: 5.128

9.  Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Authors:  Maria J Schymura; Amy R Kahn; Robert R German; Mei-Chin Hsieh; Rosemary D Cress; Jack L Finch; John P Fulton; Tiefu Shen; Erik Stuckart
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

10.  Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.

Authors:  Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong
Journal:  Med Care Res Rev       Date:  2009-04-08       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.